| Item Type | Name |
|
Academic Article
|
High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma.
|
|
Academic Article
|
Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens.
|
|
Academic Article
|
The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer.
|
|
Academic Article
|
Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas.
|
|
Academic Article
|
Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7.
|
|
Academic Article
|
Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.
|
|
Concept
|
Interleukin-1alpha
|
|
Concept
|
Interleukin-1
|
|
Concept
|
Interleukin 1 Receptor Antagonist Protein
|
|
Concept
|
Interleukin-10
|
|
Concept
|
Receptors, Interleukin-1
|
|
Concept
|
Interleukin-1beta
|
|
Concept
|
Receptors, Interleukin-2
|
|
Concept
|
Interleukin-4
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Receptors, Interleukin
|
|
Concept
|
Interleukin-2
|
|
Academic Article
|
Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
|
|
Academic Article
|
Regulation of lymphocyte tumor necrosis factor receptors by IL-2.
|
|
Academic Article
|
In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.
|
|
Academic Article
|
Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells.
|
|
Academic Article
|
Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.
|
|
Academic Article
|
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes.
|
|
Academic Article
|
Interaction of chemotherapy and biological response modifiers in the treatment of melanoma.
|
|
Academic Article
|
Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.
|
|
Academic Article
|
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
|
|
Academic Article
|
Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.
|
|
Academic Article
|
Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10.
|
|
Academic Article
|
Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes.
|
|
Academic Article
|
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
|
|
Academic Article
|
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.
|
|
Academic Article
|
Combination immunotherapy for advanced lung cancer.
|
|
Academic Article
|
IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin).
|
|
Academic Article
|
DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.
|
|
Academic Article
|
Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
|
|
Academic Article
|
The IL-2 mediated amplification of cellular cytotoxicity.
|
|
Academic Article
|
Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.
|
|
Academic Article
|
Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
|
|
Academic Article
|
Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes.
|
|
Academic Article
|
Human NK resistant tumor cell lysis is effected by IL-2 activated killer cells.
|
|
Academic Article
|
Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors.
|
|
Academic Article
|
Lymphokine-activated killer cells. Induction and function.
|
|
Academic Article
|
The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL.
|
|
Academic Article
|
Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
|
|
Academic Article
|
In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells.
|
|
Academic Article
|
Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
|
|
Academic Article
|
Inhibition of in vitro LAK generation by OK-432.
|
|
Academic Article
|
Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors.
|
|
Academic Article
|
Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
|
|
Academic Article
|
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
|
|
Academic Article
|
Suppressive immunoregulatory factors produced by tumors.
|
|
Academic Article
|
Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro.
|
|
Academic Article
|
Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
|
|
Academic Article
|
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
|
|
Academic Article
|
Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2.
|
|
Academic Article
|
Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.
|
|
Academic Article
|
Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.
|
|
Academic Article
|
Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1.
|
|
Academic Article
|
Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells.
|
|
Academic Article
|
Correlation of interleukin 6 with interleukin 1alpha in human mammary tumours, but not with oestrogen receptor expression.
|
|
Academic Article
|
Multiple interleukin-2 signaling pathways differentially regulated by microgravity.
|
|
Academic Article
|
IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway.
|
|
Academic Article
|
Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor.
|
|
Academic Article
|
MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.
|
|
Academic Article
|
mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer.
|
|
Academic Article
|
Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction.
|
|
Academic Article
|
TNF-beta (lymphotoxin) strongly upregulates TNF-alpha gene expression in human peripheral blood lymphocytes.
|
|
Academic Article
|
Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein).
|
|
Academic Article
|
Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
|
|
Academic Article
|
Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.
|
|
Academic Article
|
Molecular identification of the human tumor necrosis factor receptor on interleukin-2-stimulated peripheral blood lymphocytes.
|
|
Academic Article
|
Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
|
|
Academic Article
|
Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.
|
|
Academic Article
|
Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.
|
|
Academic Article
|
Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
|
|
Academic Article
|
Current understanding of the lymphokine-activated killer cell phenomenon.
|
|
Academic Article
|
TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.
|
|
Academic Article
|
Interleukin 2-activated cytotoxic lymphocytes in cancer therapy.
|
|
Academic Article
|
Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
|
|
Academic Article
|
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
|
|
Academic Article
|
In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor.
|
|
Academic Article
|
Interleukin-1 production in tumor cells of human melanoma surgical specimens.
|
|
Academic Article
|
Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
|
|
Academic Article
|
Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells.
|
|
Academic Article
|
Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor.
|
|
Academic Article
|
Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers.
|
|
Academic Article
|
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy.
|
|
Academic Article
|
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic.
|
|
Academic Article
|
The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells.
|
|
Academic Article
|
Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
|
|
Academic Article
|
Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells.
|
|
Academic Article
|
Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24.
|
|
Academic Article
|
IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways.
|
|
Academic Article
|
IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes.
|
|
Academic Article
|
IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells.
|
|
Academic Article
|
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
|
|
Academic Article
|
Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
|
|
Academic Article
|
Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
|
|
Academic Article
|
Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.
|
|
Academic Article
|
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.
|
|
Academic Article
|
Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
|
|
Academic Article
|
Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
|
|
Academic Article
|
Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells.
|
|
Academic Article
|
IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes.
|
|
Academic Article
|
Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines.
|
|
Academic Article
|
Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.
|
|
Academic Article
|
Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
|
|
Academic Article
|
Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte.
|
|
Academic Article
|
Inflammatory IL-1?-driven JNK activation in stage III melanoma.
|
|
Academic Article
|
Reduction of pulmonary metastases following in vivo administration of anti-CD3, interleukin-2, and tumor necrosis factor-α in mice
|
|
Academic Article
|
Enhancement of lymphokine-activated killer cell cytotoxicity with interleukin-2, tumor necrosis factor-alpha, and OKT3 against primary lung cancer targets
|
|
Academic Article
|
Interleukin-2 and cytotoxic lymphocyte therapy of primary and metastatic brain tumors
|
|
Academic Article
|
Effects of low dose OKT3 induction on the antitumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF)
|
|
Academic Article
|
IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.
|